.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

LUXIQ Drug Profile

« Back to Dashboard
Luxiq is a drug marketed by Delcor Asset Corp and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-six patent family members in twenty countries.

The generic ingredient in LUXIQ is betamethasone valerate. There are sixty-six drug master file entries for this compound. Eighteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the betamethasone valerate profile page.

Summary for Tradename: LUXIQ

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Drug Prices: :see details

Pharmacology for Tradename: LUXIQ

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Delcor Asset Corp
LUXIQ
betamethasone valerate
AEROSOL, FOAM;TOPICAL020934-001Feb 28, 1999RXYes6,126,920► subscribe ► subscribe
Delcor Asset Corp
LUXIQ
betamethasone valerate
AEROSOL, FOAM;TOPICAL020934-001Feb 28, 1999RXYes7,078,058► subscribeY ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LUXIQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Delcor Asset Corp
LUXIQ
betamethasone valerate
AEROSOL, FOAM;TOPICAL020934-001Feb 28, 19996,126,920► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LUXIQ

Drugname Dosage Strength RLD Submissiondate
betamethasone valerateFoam0.12%Luxiq8/10/2007

International Patent Family for Tradename: LUXIQ

Country Document Number Estimated Expiration
Poland322088► subscribe
Czech Republic285913► subscribe
Czech Republic9702758► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc